Intercept Using NDA Extension To Prep For AdComm Review And Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is preparing for an FDA advisory committee meeting for obeticholic acid for the treatment of primary biliary cholangitis April 7, and anticipating a commercial launch in June, all while advancing its Phase III program in NASH.